Neurocrine Biosciences | NBIX - 流动资产



金融业
股票价格
USD 141.72
资产
USD 5.36B
现金及等价物
USD 332.4M
销售成本
USD 39.4M
流动资产
USD 1.64B
流动负债
USD 874.5M
债务
USD 406.2M
EBIT
USD 219.9M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 2.85
股本和储备
USD 3.69B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 14.06B
净收入
USD 144.4M
营业费用
USD 739.1M
营业利润
USD 219.9M
普通股股本
USD 100.55M
PE价格收益
22.1
税前利润
USD 246.8M
销售收入
USD 959M
销售和管理费用
USD 383.1M
股票
USD 104.2M
贸易债权人
USD 691.3M
应收帐款人
USD 887M


流动资产 更改 日
AbbVie USD 33.67B 140M 2026-06
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
Agios Pharmaceuticals USD 717.67M 117.18M 2026-06
ALKERMES USD 1.52B 164.26M 2026-06
Alnylam Pharmaceuticals USD 4.62B 400.86M 2026-06
Amgen USD 34.96B 3.49B 2026-06
Biogen USD 7.31B 1.88B 2026-06
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Cytokinetics USD 1.21B 369.02M 2026-06
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Exelixis USD 1.25B 42.18M 2026-06
Gilead Sciences USD 12.53B 6.11B 2026-06
Halozyme Therapeutics USD 933.02M 70.01M 2026-06
Incyte USD 6.03B 542.31M 2026-06
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
Prothena USD 292.01M 47.19M 2026-06
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Repligen USD 1.2B 39.19M 2026-06
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
Teva Pharmaceutical Industries USD 13.76B 50M 2026-06
Ultragenyx Pharmaceutical USD 606M 51M 2026-06
Vertex Pharmaceuticals USD 12.54B 813.4M 2026-06